Indeed, it was demonstrated that RAD51 is a functional biomarker that enables the identification of PARP inhibitors-sensitive breast cancer cases (Castroviejo-Bermejo et al., 2018; Cruz et al., 2018). The gene discussed is RAD51; the disease is breast carcinoma.